SAMRAT PHARMACHEM
|
The Current P/E Ratio of SAMRAT PHARMACHEM is 48.70.
| Share Price | ₹246.5 | Dec 10,2025 |
| Market Cap | ₹76.4 Cr | |
| Earnings-TTM | ₹1.6 Cr | TTM-Standalone Results |
| Price/Earnings | 48.70x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of SAMRAT PHARMACHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹76.4 Cr] as on Dec 10,2025
(/) Earnings [ ₹1.6 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ 48.70x ]
Thus, for SAMRAT PHARMACHEM , the investors are currently willing to pay 48.70 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of SAMRAT PHARMACHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of SAMRAT PHARMACHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of SAMRAT PHARMACHEM
PE Ratio Performance Analysis for SAMRAT PHARMACHEM
- SAMRAT PHARMACHEM 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 16.94x.
- SAMRAT PHARMACHEM 's operated at median p/e ratio of 8.72x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, SAMRAT PHARMACHEM 's p/e ratio peaked in Mar2024 at 47.64x.
- SAMRAT PHARMACHEM 's p/e ratio hit its five-year low in Mar2023 of 6.89x.
How does SAMRAT PHARMACHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| SAMRAT PHARMACHEM | 1.57 | 48.70 | 76.4 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10,517.90 | 40.75 | 428,581.0 |
| DIVIS LABORATORIES LTD | 2,485.00 | 67.22 | 167,051.0 |
| CIPLA LTD | 5,453.86 | 22.06 | 120,289.0 |
| TORRENT PHARMACEUTICALS LTD | 2,140.00 | 59.98 | 128,367.0 |
| DR REDDYS LABORATORIES LTD | 5,721.40 | 18.25 | 104,421.0 |
| MANKIND PHARMA LTD | 1,767.06 | 50.17 | 88,649.9 |
| ZYDUS LIFESCIENCES LTD | 4,973.40 | 18.69 | 92,945.8 |
| LUPIN LTD | 4,347.53 | 21.59 | 93,866.9 |
| AUROBINDO PHARMA LTD | 3,447.75 | 19.73 | 68,035.1 |
| ABBOTT INDIA LTD | 1,508.95 | 39.47 | 59,563.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs SAMRAT PHARMACHEM 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.25x |
| Max industry PE | 67.22x |
| Median industry PE | 39.47x |
| Average industry PE | 36.97x |
You may also like the below Video Courses